Background
Open-label, multicentre, randomised phase 3 trial (TALENTOP; 24 Chinese hospitals). N=201 randomised (489 entered induction). Treatment-naive hepatocellular carcinoma with macrovascular invasion, no extrahepatic metastasis, achieving PR/SD after induction atezolizumab+bevacizumab and deemed resectable. Tests whether adding conversion liver resection to systemic therapy improves outcomes.
Results
INTERVENTIONS AND FOLLOW UP: Induction (all): atezolizumab 1200 mg + bevacizumab 15 mg/kg IV Q3W ×3 cycles + 1 cycle atezolizumab monotherapy, then randomisation.
Arm A (surgery): liver resection, then atezolizumab 1200 mg + bevacizumab 15 mg/kg IV Q3W for 12 months, started 4–6 wks post-op (n=101).
Arm B (maintenance): atezolizumab 1200 mg + bevacizumab 15 mg/kg IV Q3W until loss of clinical benefit/intolerable toxicity (n=100).
Primary endpoint: time to treatment failure (TTF) by independent review.
mFollow up: 18.4 months.
RESULTS: TTF: 20.4 vs 11.8 mo, HR 0.60, 95% CI 0.39–0.91, P=.015.
OS: NR (immature/not reported).
Arm A (surgery): liver resection, then atezolizumab 1200 mg + bevacizumab 15 mg/kg IV Q3W for 12 months, started 4–6 wks post-op (n=101).
Arm B (maintenance): atezolizumab 1200 mg + bevacizumab 15 mg/kg IV Q3W until loss of clinical benefit/intolerable toxicity (n=100).
Primary endpoint: time to treatment failure (TTF) by independent review.
mFollow up: 18.4 months.
RESULTS: TTF: 20.4 vs 11.8 mo, HR 0.60, 95% CI 0.39–0.91, P=.015.
OS: NR (immature/not reported).
Adverse events
Grade 3–4 TRAE: 39% (32/83) vs 21% (21/100).
Hepatic/lab: ALT increase 8% vs 1%; platelet decrease 8% vs 3%.
Renal: proteinuria 4% vs 7%.
Treatment-related deaths: 2 in surgery arm (abnormal liver function; liver failure).
Hepatic/lab: ALT increase 8% vs 1%; platelet decrease 8% vs 3%.
Renal: proteinuria 4% vs 7%.
Treatment-related deaths: 2 in surgery arm (abnormal liver function; liver failure).
Conclusions
In advanced HCC with macrovascular invasion responding to atezolizumab+bevacizumab, adding conversion liver resection prolonged time to treatment failure vs continued maintenance therapy. First randomised evidence supporting a surgical-conversion strategy after systemic therapy in this setting; overall survival data remain immature.
Key Limitations
Open-label; surrogate primary (TTF captures progression, extrahepatic spread, or death) rather than OS; single-country (China) and only post-induction responders randomised, limiting generalisability; higher grade 3–4 toxicity and 2 treatment-related deaths in the surgery arm; trial ongoing with immature survival.
Clinical Context
Atezolizumab+bevacizumab (IMbrave150) is a global first-line standard for unresectable advanced HCC; resection is not standard for macrovascular-invasion disease. TALENTOP is investigational proof-of-concept for a response-adapted conversion-surgery approach and is not yet reflected in FDA labeling or NCCN/ESMO guidelines, which do not endorse routine resection after systemic therapy in this population.